AGP Executive Report
Last update: an hour agoDrug Safety: Pakistan’s health minister threatened legal action and plant closures for drugmakers that fail to submit required 2D-barcode data; about 80% have begun compliance as the country seeks to curb counterfeit medicines. Heart Health: An autopsy study found more heart enlargement, scarring and inflammation among people with lupus or rheumatoid arthritis, with some differences more pronounced in younger patients. In a separate study of 27,382 people, AI-based cardiac MRI measurements predicted death slightly better than clinicians’ and took seconds rather than minutes. Infection Treatment: U.S. surveillance found ceftobiprole active against nearly 99% of MRSA isolates, but only 73% of E. coli and Klebsiella isolates overall. Care Access: Asia Healthcare Holdings is investing ₹100 crore in a new kidney and urology hospital in Bhubaneswar; meanwhile, WHO warns that violence and shortages are pushing Ethiopia’s health system toward collapse. New Treatment: FDA granted accelerated approval to INOVIO’s Voceryq for recurrent respiratory papillomatosis, aiming to reduce the need for surgery; continued approval depends on confirmatory testing.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
